PF-543 inhibitor shows promise against leishmaniasis in dual-target approach

Leishmaniasis kills tens of thousands of people each year, mostly in poor countries where the disease thrives. The parasites that cause it—Leishmania donovani—burrow into the immune cells meant to destroy them, hijacking the host's own chemistry to survive and multiply. The drugs that work against leishmaniasis are old, toxic, and increasingly useless as the parasites develop resistance. Researchers at Jawaharlal Nehru University set out to find a new angle of attack, and what they discovered points toward a fundamentally different way of fighting the disease: stop helping the parasite, rather than just poisoning it.

The team focused on an enzyme called sphingosine kinase 1, or SphK1. Both the parasite and the human immune cell possess this enzyme, and both use it to regulate lipid signaling—the chemical conversations that keep cells alive and functioning. The researchers tested PF-543, a drug originally developed to fight cancer by blocking SphK1. In laboratory dishes, PF-543 proved potent against the parasite's free-swimming form, with an inhibitory concentration of 450 nanomolar. Against the parasite hiding inside macrophages—the actual form that causes disease—it was less effective but still meaningful. Critically, the drug barely touched human immune cells at concentrations that harmed parasites, suggesting a therapeutic window wide enough to work with.

What made this finding unusual was its dual nature. PF-543 did not simply poison the parasite. Instead, it worked on both sides of the infection simultaneously. When researchers treated infected macrophages with PF-543, the parasite burden dropped by roughly 40 percent per infected cell. At the same time, the drug shifted the immune response. It suppressed the anti-inflammatory cytokine IL-10—a molecule the parasite exploits to keep the immune system quiet—while leaving pro-inflammatory signals intact. The treated macrophages also showed signs of apoptosis, programmed cell death, which can eliminate infected cells before parasites escape. The mechanism was not a direct kill shot but a rebalancing of the host-parasite relationship in favor of the host.

To understand how this worked at the molecular level, the researchers cloned and purified both the parasite's SphK1 and the human version. They found that PF-543 binds to each enzyme differently. In the human protein, the drug anchors itself via hydrogen bonds to a specific aspartate residue. In the parasite enzyme, it binds to a different arginine residue. This distinction mattered: it meant the drug could potentially be tuned to favor one target over the other, or to hit both with acceptable selectivity. The binding affinity was modest—a dissociation constant of 29.3 micromolar for the parasite enzyme and 34.3 micromolar for the human one—but sufficient for functional inhibition.

The real promise emerged when researchers combined PF-543 with amphotericin B, the current clinical standard for visceral leishmaniasis. In test tubes, the two drugs worked synergistically. Amphotericin B alone required 30 nanomolar to inhibit half the parasites; PF-543 alone required 500 nanomolar. Together, they achieved the same effect at 12.5 nanomolar and 150 nanomolar respectively—a dramatic reduction in the doses needed. The researchers then moved to living animals. Swiss mice infected with Leishmania donovani received either drug alone or both together. The combination therapy drastically lowered parasite burden in the spleen, the organ most affected by visceral leishmaniasis. Mice tolerated both drugs well at the doses used, with no significant toxicity observed.

What emerges from this work is a new therapeutic principle: targeting the host's own enzymes, rather than parasite-specific ones, may offer advantages. The parasite depends on the host cell's machinery to survive. By modulating that machinery—by tipping the balance toward inflammation and cell death—researchers can make the host cell a hostile environment without relying on drugs that the parasite might eventually resist. PF-543 is not a cure by itself, but as a proof of concept, it suggests that the next generation of leishmaniasis treatments might work by making the host's defenses work better, not by finding ever more potent poisons.